ReviewClinical and experimental nephrology2014
Causes and consequences of lipoprotein(a) abnormalities in kidney disease.
Review in Clinical and experimental nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- A Systematic Review on the Risk Modulators of Myocardial Infarction in the "Young"-Implications of Lipoprotein (a).International journal of molecular sciences · 2023Pooled it
- Association Between Lipoprotein (A) and Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Lipoprotein(a) Lipidome: Responses to Reduced Dietary Saturated Fat Intake in Two Randomized Controlled Feeding Trials.Nutrients · 2025Trial
- Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome.International journal of molecular sciences · 2026Review
- Lp(a) Has Specific Effects on Coronary Artery Disease Independent of LDL-C: A Mendelian Randomization Study.JACC. Advances · 2026Article
- The biology of lipoprotein(a): From genetics to molecular mechanisms.European journal of clinical investigation · 2026Review
- Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies.European journal of clinical investigation · 2026Review
- Lipoprotein(a) levels predict endothelial dysfunction in maintenance hemodialysis patients: evidence from vascular reactivity index assessment.Renal failure · 2025Article
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Novel Therapy in the Treatment of Cholesterol Crystal Embolism-Induced Kidney Injury.Kidney medicine · 2025Article
- Lipoprotein(a) and coronary artery disease: The need for universal screening - A case-based review.American heart journal plus : cardiology research and practice · 2025Review
- Lipoprotein(a) Response to Dietary Saturated Fat Reduction: Relationship to Apolipoprotein(a) Size Polymorphism in African Americans.Nutrients · 2025Article
- Is lipoprotein(a) measurement important for cardiovascular risk stratification in children and adolescents?Italian journal of pediatrics · 2024Article
- The implications of measuring lipoprotein(a) in clinical practice.Global cardiology science & practice · 2024Article
- Initial decrease in the lipoprotein(a) level is a novel prognostic biomarker in patients with acute coronary syndrome.World journal of cardiology · 2024Article
- Relationship Between Lipoprotein(a), Renal Function Indicators, and Chronic Kidney Disease: Evidence From a Large Prospective Cohort Study.JMIR public health and surveillance · 2024Article
- Lipoprotein(a): Role in atherosclerosis and new treatment options.Biomolecules & biomedicine · 2023Review
- Prognostic impacts of diabetes status and lipoprotein(a) levels in patients with ST-segment elevation myocardial infarction: a prospective cohort study.Cardiovascular diabetology · 2023Article
- Evidence and Uncertainties on Lipoprotein(a) as a Marker of Cardiovascular Health Risk in Children and Adolescents.Biomedicines · 2023Review
- Supporting evidence for lipoprotein(a) measurements in clinical practice.Best practice & research. Clinical endocrinology & metabolism · 2023Review
- Association between Lipoprotein(a) and diabetic nephropathy in patients with type 2 diabetes.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoprotein(a) is one of the strongest genetically determined risk factors for cardiovascular disease, and patients with chronic kidney disease have major disturbances in lipoprotein(a) metabolism. Concentrations are increased and are influenced by glomerular filtration rate (GFR) and the amount of proteinuria. The reason for this elevation can be increased synthesis, as is the case for patients with nephrotic syndrome or those treated by peritoneal dialysis. In hemodialysis patients, a catabolic block is the reason for this elevation. The elevated concentrations might contribute to the tremendous cardiovascular risk in this particular population. In particular, the genetically determined small apolipoprotein(a) isoforms are associated with an increased risk for cardiovascular events and total mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.